6518.TWO Concord Medical Co., Ltd.
- Market cap
- TWD 1.05B
- P/E
- 11.5x
- P/B
- 1.39x
- ROE
- 9.3%
- Dividend yield
- 3.50%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 6518.TWO undervalued?
Graham number6518.TWO trades 15.4% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Concord Medical Co., Ltd. fundamental analysis
No fundamental analysis for Concord Medical Co., Ltd. yet.
Concord Medical Co., Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Concord Medical Co., Ltd.
Concord Medical Co., Ltd. provides hospital management support services primarily in Taiwan. The company offers medical management services that include medical training and nursing staffing and assisting on medical management; and procurement services for instruments and equipment, drugs, medical materials and consumables, testing equipment, and reagents and consumables, as well as develops its own brand for medical aesthetic skincare products, health foods, and topical Chi…
Full company profileConcord Medical Co., Ltd. financial statements
Concord Medical Co., Ltd. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 764M | 810M | 739M | 889M | 833M | 890M | 964M |
| Gross Profit | 76.1M | 64.4M | 68.5M | 109M | 102M | 110M | 134M |
| Operating Income | 42.0M | 28.1M | 37.5M | 64.8M | 54.9M | 61.8M | 72.8M |
| EBITDA | 124M | 135M | 144M | 143M | 137M | 152M | 172M |
| Net Income | 31.4M | 19.8M | 34.4M | 50.7M | 42.7M | 49.6M | 67.4M |
| EPS | 1.25 | 0.79 | 1.37 | 1.52 | 1.28 | 1.48 | 2.02 |
| Balance Sheet | |||||||
| Total Assets | 1.11B | 1.09B | 1.08B | 1.18B | 1.15B | 1.16B | 1.22B |
| Total Liabilities | 604M | 575M | 445M | 464M | 471M | 467M | 466M |
| Shareholders' Equity | 503M | 513M | 638M | 672M | 681M | 697M | 728M |
| Cash & Short-term Investments | 51.9M | 62.3M | 202M | 347M | 320M | 321M | 125M |
| Total Debt | 358M | 345M | 217M | 198M | 216M | 211M | - |
| Cash Flow | |||||||
| Operating Cash Flow | 131M | 84.1M | 137M | 155M | 113M | 149M | 157M |
| Capital Expenditure | 69.9M | 94.0M | 21.9M | 38.1M | 89.7M | 76.4M | 35.3M |
| Free Cash Flow | 61.1M | -9.92M | 115M | 116M | 23.5M | 72.5M | 122M |
| Ratios | |||||||
| ROE | 6.2% | 3.9% | 5.4% | 7.5% | 6.3% | 7.1% | 9.3% |
| ROA | 2.8% | 1.8% | 3.2% | 4.3% | 3.7% | 4.3% | 5.5% |
| Net Profit Margin | 4.1% | 2.4% | 4.7% | 5.7% | 5.1% | 5.6% | 7.0% |
| Debt to Equity | 0.71x | 0.67x | 0.34x | 0.29x | 0.32x | 0.30x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Concord Medical Co., Ltd. dividends
- Dividend yield
- 3.50%
- Forward dividend
- 1.50 TWD
- Payout ratio
- 54.4%
- Ex-dividend date
- Apr 10, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 36.7M | 1.10 | 54.4% |
| 2024 | TWD 33.3M | 1.00 | 67.2% |
| 2023 | TWD 33.3M | 1.00 | 78.0% |
| 2022 | TWD 16.7M | 0.50 | 32.9% |
| 2021 | TWD 10.0M | 0.40 | 29.1% |
| 2020 | 10.0M | 0.40 | 50.6% |
| 2019 | 10.0M | 0.40 | 31.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Concord Medical Co., Ltd.
Ownership data of Concord Medical Co., Ltd. is not available yet.
Concord Medical Co., Ltd. company profile
- Company name
- Concord Medical Co., Ltd.
- Ticker
- 6518.TWO
- ISIN
- TW0006518004
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Fiscal year end
- December
- Address
- No. 266, Wenhua Road, New Taipei City, Taiwan, 22041
- Phone
- 886 2 2254 5049
- Website
- concordmed.com.tw
About Concord Medical Co., Ltd.
Concord Medical Co., Ltd. provides hospital management support services primarily in Taiwan. The company offers medical management services that include medical training and nursing staffing and assisting on medical management; and procurement services for instruments and equipment, drugs, medical materials and consumables, testing equipment, and reagents and consumables, as well as develops its own brand for medical aesthetic skincare products, health foods, and topical Chinese medicine products. It is also involved in the medical equipment planning and sales; and medical equipment leasing activities. The company was founded in 2009 and is headquartered in New Taipei City, Taiwan.
Concord Medical Co., Ltd. management
4- Jianling HonGM & Director
- Fuan LiuCFO & Director
- Weiting LuAccounting Supervisor
- Mr. Yangren LaiDeputy General Manager